Zentalis Pharmaceuticals

ZNTL · NASDAQ

$2.39+$0.09 (+3.91%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.30

Latest news

Press releaseOct 18, 6:05 PM ETGlobe Newswire
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
NewsSep 16, 1:38 PM ETVandana Singh
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
Press releaseSep 2, 4:05 PM ETGlobe Newswire
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Press releaseAug 17, 4:01 PM ETGlobe Newswire
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NewsAug 14, 8:06 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseAug 13, 10:23 PM ETGlobe Newswire
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
NewsAug 13, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsAug 13, 4:05 PM ET
Zentalis Pharmaceuticals Announces Proposed Public Offering Of Shares And Pre-Funded Warrants
Press releaseAug 13, 4:01 PM ETGlobe Newswire
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Press releaseAug 6, 4:05 PM ETGlobe Newswire
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Press releaseJul 17, 4:15 PM ETGlobe Newswire
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
NewsJul 17, 10:09 AM ETAvi Kapoor
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Press releaseMay 27, 4:05 PM ETGlobe Newswire
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
Press releaseMay 21, 5:39 PM ETGlobe Newswire
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
NewsApr 29, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsApr 10, 2:10 PM ETAvi Kapoor
Nasdaq Moves Higher; US Inflation Rate Accelerates In March
NewsApr 10, 12:44 PM ETAlex Perry
What's Behind The Surge In Zentalis Stock?
NewsApr 9, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsFeb 24, 4:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseJan 12, 10:35 AM ETPRNewswire
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
NewsMay 14, 4:20 PM ET
Zentalis Pharma Q1 EPS $(0.67) Misses $(0.63) Estimate
Press releaseMay 14, 4:05 PM ETGlobe Newswire
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
NewsMar 26, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseMar 26, 4:05 PM ETGlobe Newswire
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Press releaseFeb 25, 4:40 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseFeb 19, 9:00 AM ETBusiness Wire
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting
Press releaseFeb 18, 7:04 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseFeb 11, 3:22 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseFeb 4, 3:05 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseDec 10, 2:32 PM ETPRNewswire
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
Press releaseSep 16, 9:38 PM ETPRNewswire
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
NewsSep 16, 8:08 AM ET
Market-Moving News for September 16th
Press releaseAug 19, 4:55 PM ETBusiness Wire
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
Press releaseAug 15, 4:00 PM ETGlobe Newswire
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Press releaseAug 13, 4:00 PM ETBusiness Wire
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Press releaseAug 9, 4:00 PM ETGlobe Newswire
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Press releaseAug 4, 4:00 PM ETGlobe Newswire
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Press releaseAug 3, 4:11 PM ETGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseAug 2, 10:00 AM ETPRNewswire
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Press releaseAug 1, 7:25 PM ETBusiness Wire
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Press releaseAug 1, 6:55 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseJul 26, 10:43 AM ETGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseJul 25, 2:49 PM ETPRNewswire
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
Press releaseJul 24, 8:00 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
Press releaseJul 12, 10:08 AM ETGlobe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 Health Care Stocks Moving In Friday's Pre-Market Session

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

12 Health Care Stocks Moving In Thursday's After-Market Session

Zentalis Pharmaceuticals Announces Proposed Public Offering Of Shares And Pre-Funded Warrants

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session

Nasdaq Moves Higher; US Inflation Rate Accelerates In March

What's Behind The Surge In Zentalis Stock?

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

Zentalis Pharma Q1 EPS $(0.67) Misses $(0.63) Estimate

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

12 Health Care Stocks Moving In Wednesday's After-Market Session

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Market-Moving News for September 16th

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL